Presenter: Jud Kimmel, Neuroendocrine Cancer Patient / Advocate

Date: Wednesday, March 25, 2026
Time: 3:30pm – 4:30pm EDT

After a year+ of worsening symptoms and diagnostic dead ends, Jud Kimmel was diagnosed with Stage IV, Grade 3 Small Bowel Neuroendocrine Tumor (NET) in September 2022.  Jud received Lu-177 Dotatate as his first-line treatment via the NETTER-2 clinical trial, and later underwent a total tumor resection and ablation that was made possible by RLT’s effect on Jud’s 25 visible NETs in the small bowel, mesentery, and liver.  Although Stage IV NET is considered incurable, Jud is using his current NEAD (no evidence of active disease) status to educate and support other cancer patients, including in questions of nuclear medicine and molecular imaging.

Jud lives in Saint Paul, Minnesota with his wife and one kid (of three) still at home.

In this session, Jud will help you to:

• understand psychological challenges common to today’s cancer patient – that is, with unlimited access to medical information, including their own records.
• learn how these challenges are a foundation upon which prospective and actual RLT patients then develop several RLT-specific concerns and perceptions.
• discuss concrete ways to enhance provider – patient communication and trust around radioligand therapies and theranostics more generally.

Approved for 1.0 CEH credit from SNMMI.